SEC Filing Summary: AVI BioPharma, Inc. (10-Q)
Business Context and Reporting Period
This filing is a Quarterly Report on Form 10-Q for AVI BioPharma, Inc., a biopharmaceutical company focused on RNA-based therapeutics for rare and infectious diseases. The report covers the quarterly period ended September 30, 2010. The company is classified as a development-stage entity with no commercial product sales to date. Revenue is derived almost exclusively from U.S. government research contracts.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2010 | Nine Months Ended Sep 30, 2010 | Balance Sheet (Sep 30, 2010) |
|---|---|---|---|
| Revenue | $8,702 | $13,903 | N/A |
| Operating Loss | $(3,797) | $(19,194) | N/A |
| Net Loss | $(7,293) | $(24,533) | N/A |
| Cash and Cash Equivalents | N/A | N/A | $35,967 |
| Total Assets | N/A | N/A | $50,860 |
| Total Liabilities | N/A | N/A | $46,697 |
| Shareholders' Equity | N/A | N/A | $4,163 |
| Accumulated Deficit | N/A | N/A | $(300,002) |
Note: The company reported a significant non-cash liability for warrants valued at $33.1 million, which fluctuates based on stock price and volatility.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 37% ($2.3 million) for the three months ended September 30, 2010, compared to the same period in 2009. This was driven by new U.S. government contracts for H1N1 and Ebola/Marburg programs, partially offset by lower revenue from a Children's National Medical Center contract.
- Expense Increases:
- Research & Development (R&D): Increased 21% ($1.6 million) quarter-over-quarter due to upfront payments to contract research organizations (CROs) for the H1N1 program and increased staffing costs.
- General & Administrative (G&A): Increased 91% ($1.6 million) quarter-over-quarter. This spike was primarily due to $2.6 million in severance costs and stock compensation related to the departure of the former CEO in April 2010, along with increased legal and professional fees.
- Warrant Liability: The company recorded a non-cash loss of $3.6 million for the quarter and $5.5 million for the nine-month period due to the mark-to-market adjustment of warrant liabilities.
- Liquidity: Cash and cash equivalents decreased from $48.3 million at year-end 2009 to $36.0 million at September 30, 2010, reflecting a net cash outflow of $12.3 million for the nine-month period.
Guidance, Outlook, and Risks
- Government Contract Outlook: The company expects future revenues and R&D costs to increase due to new contracts. As of September 30, 2010, the company had contracts with the U.S. government for up to $157.2 million in aggregate funding, with $95.0 million remaining unbilled for future development work.
- Key Contracts:
- July 2010 Agreement: A new contract with the DoD for Ebola and Marburg therapeutics (AVI-6002 and AVI-6003) with potential funding of up to $291 million over six years if all options are exercised.
- June 2010 Agreement: An $18 million contract for H1N1 influenza countermeasure (AVI-7100).
- Liquidity Position: Management believes current cash resources are sufficient to finance operations for at least the next 12 months, excluding future government contract proceeds. However, the company expects to incur operating losses for the foreseeable future and will require additional capital to continue development.
- Risks:
- Regulatory Approval: Product candidates are in early stages; there is no assurance of FDA approval or commercial success.
- Government Funding: Revenue is heavily dependent on U.S. government contracts, which are subject to appropriation delays or termination.
- Leadership Transition: The company is operating under an interim CEO following the resignation of the former CEO in April 2010.
- Warrant Volatility: Fluctuations in stock price significantly impact reported net loss due to warrant liability accounting.
Investor Verification Checklist
- Government Contract Reliance: Verify the status of the $157.2 million in government contracts and the risk of funding delays or termination.
- Warrant Liability Impact: Assess the sensitivity of the $33.1 million warrant liability to stock price volatility and its effect on reported net loss.
- Cash Burn Rate: Confirm the sufficiency of the $36.0 million cash balance against the projected R&D spend for the next 12 months.
- CEO Search: Monitor the progress of the search for a permanent CEO to ensure strategic continuity.
- Clinical Trial Progress: Track the status of Phase 1 trials for AVI-7100 (H1N1) and AVI-6002/6003 (Ebola/Marburg) and the analysis of AVI-4658 (DMD) data.